Gland Pharma gets USFDA’s approval for Edaravone Injection

07 May 2024 Evaluate

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL) and 60 mg/100 mL (0.6 mg/mL), Single-Dose Bags. The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Radicava Injection, 30 mg/100 mL (0.3 mg/mL) and 60 mg/100 mL (0.6 mg/mL) of Mitsubishi Tanabe Pharma Corporation.

The Product is used to treat amyotrophic lateral sclerosis (ALS), a condition in which the nerves that control muscle movement slowly die, causing the muscles to shrink and weaken. The Company expects to launch this Product through its marketing partner within FY25. According to IQVIA, the product had US sales of approximately $19 million for the twelve months ending January 2024.

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.


Gland Pharma Share Price

1768.35 -23.40 (-1.31%)
18-May-2024 12:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.85
Dr. Reddys Lab 5812.50
Cipla 1403.90
Zydus Lifesciences 1104.45
Lupin 1661.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.